Cover Image
市場調查報告書

帕金森氏症治療藥的全球市場的預測 (2018∼2028年):各產品 (卡比多巴,多巴胺受體激動劑,MAO抑制劑,COMT抑制劑,抗膽鹼促效劑)、各流通管道、各終端用戶

Global Parkinson's Disease Drug Market Forecast 2018-2028: Carbidopa, Dopamine Receptor Antagonists, MAO-Inhibitors, COMT-Inhibitors, Anticholinergics, Distribution Channels and End-Users

出版商 Visiongain Ltd 商品編碼 220572
出版日期 內容資訊 英文 152 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
帕金森氏症治療藥的全球市場的預測 (2018∼2028年):各產品 (卡比多巴,多巴胺受體激動劑,MAO抑制劑,COMT抑制劑,抗膽鹼促效劑)、各流通管道、各終端用戶 Global Parkinson's Disease Drug Market Forecast 2018-2028: Carbidopa, Dopamine Receptor Antagonists, MAO-Inhibitors, COMT-Inhibitors, Anticholinergics, Distribution Channels and End-Users
出版日期: 2018年01月22日 內容資訊: 英文 152 Pages
簡介

本報告提供全球帕金森氏症治療藥的市場調查,帕金森氏症其治療相關概要,市場成長的推動、阻礙要素,定性分析 (市場向心力),整體市場規模的變化與預測 (今後11年份),各產品種類、各流通管道及各地區詳細趨勢、預測,主要企業的簡介,市場競爭、資本交易的動向 (M&A等) 等彙整資料。

第1章 分析概要

第2章 全球帕金森氏症治療藥的產業、市場:簡介

第3章 全球帕金森氏症治療藥的產業、市場未來預測 (到2028年)

第4章 市場預測:各醫藥品類型 (到2028年)

  • 概要
  • 左旋多巴/卡比多巴
  • 多巴胺受體激動劑
  • 單胺氧化酵素 (MAO) 抑制劑
  • 兒茶酚-O-甲基轉移酵素 (COMT) 抑制劑
  • 抗膽鹼促效劑
  • 其他的醫藥品

第5章 到市場預測:各流通管道 (2028年)

  • 概要
  • 院內藥局
  • 零售藥局
  • 線上藥局

第6章 到市場預測:各終端用戶 (2028年)

  • 概要
  • 醫院
  • 診療所

第7章 主要國家的帕金森氏症治療藥市場 (今後11年份)

第8章 北美市場預測 (今後11年份)

  • 美國
  • 加拿大
  • 墨西哥

第9章 南美市場預測 (今後11年份)

  • 巴西
  • 阿根廷
  • 巴拉圭
  • 玻利維亞
  • 其他

第10章 歐洲市場預測 (今後11年份)

  • 法國
  • 德國
  • 英國
  • 西班牙
  • 義大利
  • 俄羅斯
  • 其他

第11章 亞太地區市場預測 (今後11年份)

  • 中國
  • 日本
  • 印度
  • 澳洲
  • 泰國
  • 其他

第12章 其他的國家 (RoW)的市場預測 (今後11年份)

  • 中東
  • 非洲
  • 其他

第13章 定性分析 (今後11年份)

  • 波特的五力分析
    • 買主談判力 (低)
    • 供應商談判力 (中)
    • 新加入企業的威脅 (低)
    • 替代產品的威脅 (低)
    • 企業間競爭的激烈程度 (高)
  • 推動及阻礙市場要素,市場機會
    • 推動市場要素
    • 阻礙市場要素
    • 市場機會

第14章 全球帕金森氏症治療藥市場代表性企業

  • AstraZeneca Plc
    • 企業概要
    • 產品系列
    • 近幾年趨勢
  • Merck & Co. Inc.
  • Novartis AG
  • GlaxoSmithKline PLC
  • F. Hoffmann-La Roche AG
  • Pfizer Inc.
  • Abbvie Inc.
  • Biogen Inc.
  • Acorda Therapeutics, Inc.
  • UCB S.A.

第15章 結論

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0277

Our new study reveals trends, R&D progress, and predicted revenues

Our new report discusses issues and events affecting the Parkinson's disease therapeutics market. Our new report provides qualitative analyses to answer these key questions:

  • How is the Parkinson's disease therapeutics market evolving?
  • What is driving and restraining the Parkinson's disease therapeutics market?
  • How will political and regulatory factors influence the regional markets and submarkets?
  • Who are the leading Parkinson's disease therapeutics companies, and what are their prospects over the forecast period?
  • What are the predictions for M&A activity, consolidation for existing players and the potential prospects for new market entrants?

Forecasts from 2018-2028 and other analyses show you commercial prospects

Our new report provides quantitative analyses to answer these key questions:

  • What are the market shares of the Parkinson's therapeutics disease market in 2017?
  • How will each of the drugs in the Parkinson's therapeutics market grow over the forecast period and how much revenue will these drugs account for in 2028?
  • What Parkinson's disease drugs are in the development pipeline?
  • How will each of Parkinson's disease diagnostics market grow over the forecast period and how much revenue will these submarkets account for in 2028?
  • How will the market shares of the national markets change by 2028 and which geographical region will lead the market in 2028?

Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. We provide original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and STEP), company profiles and commercial developments.

Many opportunities exist for the treatment of Parkinson's. Our new study shows you the most promising and lucrative parts of that CNS market, helping you stay ahead.

Discover sales predictions for the world market and submarkets

Discover in our report overall world revenue to 2028 for Parkinson's disease medicines. Also explore individual revenue predictions to 2028 for six therapeutic submarkets at world level:

  • Levodopa/ Carbidopa
  • Dopamine Receptor Agonists
  • MAO-inhibitors
  • COMT-inhibitors
  • Anticholinergics
  • Other Therapeutic Options

Each submarket is further broken down by region : North America, South America, Europe, Asia-Pacific and ROW.

Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

This report also breaks down the revenue forecast for the Global Parkinson's Disease drugs market by Distribution Channel:

  • Hospital Pharmacies
  • Retailer Pharmacies
  • Online Pharmacies

Each submarket is further broken down by region : North America, South America, Europe, Asia-Pacific and ROW.

This report also breaks down the revenue forecast for the Global Parkinson's Disease drugs market by End-User :

  • Hospitals
  • Clinics

Each submarket is further broken down by region : North America, South America, Europe, Asia-Pacific and ROW.

What are the prospects in the leading regions and countries?

Developments worldwide expand the market for diagnosing, treating and monitoring neurodegenerative disorders. Developed and developing national markets hold high potential from 2017.

Our work also shows individual revenue forecasts to 2028 for 20 national markets:

  • North America - US, Canada, Mexico
  • South America - Brazil, Argentina, Paraguay, Bolivia
  • Europe - Germany, France, UK, Italy, Spain and Russia
  • Asia Pacific - China, Japan, India, Australia, Thailand
  • ROW - Middle East, Africa

**1

Leading companies and potential for market growth

In 2017 the overall Global Parkinson's Disease drug market generated $4.10bn. Visiongain predicts its revenues in 2022 to reach $5.70bn. Our work shows you what organisation hold greatest potential. See profiles of leading companies in this sector:

  • Astrazeneca
  • Merck &Co.
  • Novartis AG
  • GlaxoSmith Kline
  • Roche
  • Pfizer
  • Abbvie
  • Biogen Inc.
  • Acorda Therapeutics Inc

What affects producers of those medicines?

Our report discusses issues and events affecting that industry and market from 2017, including these:

  • Research and development (R&D) - drugs, diagnostic tests, and related technologies
  • Disease prevalence - expanding patient populations
  • Disease-modifying drugs and obstacles to cures
  • Regulatory guidelines - changes and opportunities.
  • Drugs and related technologies to transform the market
  • Biomarkers
  • Deep brain stimulation (functional neuromodulation)
  • Intellectual property (IP), licensing agreements and partnerships.

Our 152-page report provides 82 Tables and 85 Figures . Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews trends and opportunities, and revenue predictions.

Benefit your work now through our updated study, gaining original industry and market analysis:

  • Revenues for Parkinson's disease treatments to 2028 - assess that overall world drugs market's potential and get forecasted revenues for the six leading sub-classes: Levodopa/Carbidopa, Dopamine receptor agonists, COMT- and MAO-inhibitors, Anticholinergics, and other therapeutic options.
  • National market forecasting to 2028 for 20 countries in the Americas, Europe, Asia, Middle East and Africa - explore the best regions for treatment demand, sales and growth
  • R&D activities - see progress, trends and prospects in research and development, finding technological, clinical and commercial possibilities
  • Analysis of what stimulates and restrains that industry and market - assess challenges and strengths there, helping you compete and gain advantages.

Table of Contents

1. Report Overview

  • 1.1 Global Parkinson's Disease Drug Industry and Market Overview
  • 1.2 Market Definition
  • 1.3 Research Methodology
  • 1.4 Primary Research
  • 1.5 Secondary Research
  • 1.6 Market Evaluation & Forecasting Methodology
  • 1.7 Global Parkinson's Disease Drug industry and Market Segmentation
  • 1.8 Overview of Findings
  • 1.9 Why You Should Read This Report
  • 1.10 How this report delivers?
  • 1.11 Key Questions Answered by This Analytical Report
  • 1.12 Frequently Asked Questions (FAQ)
  • 1.13 Who is This Report For?
  • 1.14 Associated Visiongain Reports
  • 1.15 About Visiongain

2. Introduction to Global Parkinson's Disease Drug Industry and Market

3. Global Parkinson's Disease Drug Industry and Market Forecast to 2028

4. Global Parkinson's Disease Market, by Drug Type: Market Forecast to 2028

  • 4.1 Overview
  • 4.2 Levodopa/Carbidopa
  • 4.3 Dopamine Receptor Agonists
  • 4.4 MAO-Inhibitors
  • 4.5 COMT-inhibitors
  • 4.6 Anticholinergics
  • 4.7 Other Drugs

5. Global Parkinson's Disease Drug Industry and Market by Distribution Channel: Market Forecast to 2028

  • 5.1 Overview
  • 5.2 Hospital Pharmacies
  • 5.3 Retailer Pharmacies
  • 5.4 Online Pharmacies

6. Global Parkinson's Disease Drug Industry and Market by End User: Market Forecast to 2028

  • 6.1 Overview
  • 6.2 Hospitals
  • 6.3 Clinics

7. Leading National Parkinson's Disease Drug Markets, 2018-2028

8. North American Parkinson's Disease Drug Industry and Forecast 2018-2028

  • 8.1 US Parkinson's Disease Drug Industry and Forecast 2018-2028
  • 8.2 Canada Parkinson's Disease Drug Industry and Forecast 2018-2028
  • 8.3 Mexico Parkinson's Disease Drug Industry and Forecast 2018-2028

9. South American Parkinson's Disease Drug Industry and Forecast 2018-2028

  • 9.1 Brazil Parkinson's Disease Drug Industry and Forecast 2018-2028
  • 9.2 Argentina Parkinson's Disease Drug Industry and Forecast 2018-2028
  • 9.3 Paraguay Parkinson's Disease Drug Industry and Forecast 2018-2028
  • 9.4 Bolivia Parkinson's Disease Drug Industry and Forecast 2018-2028
  • 9.5 Rest of South America Parkinson's Disease Drug Industry and Forecast 2018-2028

10. European Parkinson's Disease Drug Industry and Forecast 2018-2028

  • 10.1 France Parkinson's Disease Drug Industry and Forecast 2018-2028
  • 10.2 Germany Parkinson's Disease Drug Industry and Forecast 2018-2028
  • 10.3 UK Parkinson's Disease Drug Industry and Forecast 2018-2028
  • 10.4 Spain Parkinson's Disease Drug Industry and Forecast 2018-2.028
  • 10.5 Italy Parkinson's Disease Drug Industry and Forecast 2018-2028
  • 10.6 Russia Parkinson's Disease Drug Industry and Forecast 2018-2028
  • 10.7 Rest of Europe Parkinson's Disease Drug Industry and Forecast 2018-2028

11. Asia-Pacific Parkinson's Disease Drug Industry and Forecast 2018-2028

  • 11.1 China Parkinson's Disease Drug Industry and Forecast 2018-2028
  • 11.2 Japan Parkinson's Disease Drug Industry and Forecast 2018-2028
  • 11.3 India Parkinson's Disease Drug industry and Forecast 2018-2028
  • 11.4 Australia Parkinson's Disease Drug Industry and Forecast 2018-2028
  • 11.5 Thailand Parkinson's Disease Drug Industry and Forecast 2018-2028
  • 11.6 Rest of Asia-Pacific Parkinson's Disease Drug Industry and Forecast 2018-2028

12. Rest of World Parkinson's Disease Drug Industry and Forecast 2018-2028

  • 12.1 Middle East Parkinson's Disease Drug Industry and Forecast 2018-2028
  • 12.2 Africa Parkinson's Disease Drug Industry and Forecast 2018-2028
  • 12.3 Other Countries Parkinson's Disease Drug Industry and Forecast 2018-2028

13. Parkinson's Disease Drug industry and Forecast, Qualitative Analysis, 2018-2028

  • 13.1 Porter's Five Forces Analysis of the Global Parkinson's disease drug industry and Forecast 2018-2028
    • 13.1.1 Bargaining Power of Buyers (Low)
    • 13.1.2 Bargaining Power of Suppliers (Medium)
    • 13.1.3 Threat of New Entrants (Low)
    • 13.1.4 Threat of Substitute Products (Low)
    • 13.1.5 Intensity of Competitive Rivalry (High)
  • 13.2 Drivers, Restrains & Opportunities
    • 13.2.1 Drivers
    • 13.2.2 Restraints
    • 13.2.3 Opportunities

14. Leading Companies in the Global Parkinson's Disease Drugs Market

  • 14.1 AstraZeneca Plc
    • 14.1.1 AstraZeneca Plc: Company Overview
    • 14.1.2 AstraZeneca Plc: Product Portfolio
    • 14.1.3 AstraZeneca Plc: Recent Developments
  • 14.2 Merck & Co. Inc.
    • 14.2.1 Merck & Co. Inc.: Company Overview
    • 14.2.2 Merck & Co. Inc.: Product Portfolio
  • 14.3 Novartis AG
    • 14.3.1 Novartis AG: Company Overview
    • 14.3.2 Novartis AG: Product Portfolio
  • 14.4 GlaxoSmithKline PLC
    • 14.4.1 GlaxoSmithKline PLC: Company Overview
    • 14.2 GlaxoSmithKline PLC: Product Portfolio
  • 14.5 F. Hoffmann-La Roche AG
    • 14.5.1 F. Hoffmann-La Roche: Company Overview
    • 14.5.2 F. Hoffmann-La Roche: Product Portfolio
    • 14.5.3 F. Hoffmann-La Roche: Recent Developments
  • 14.6 Pfizer Inc.
    • 14.6.1 Pfizer Inc.: Company Overview
    • 14.6.2 Pfizer Inc.: Product Portfolio
    • 14.6.3 Pfizer: Recent Developments
  • 14.7 Abbvie Inc.
    • 14.7.1 Abbvie Inc.: Company Overview
    • 14.7.2 Abbvie Inc.: Product Portfolio
    • 14.7.3 Abbvie Inc.: Recent Developments
  • 14.8 Biogen Inc.
    • 14.8.1 Biogen Inc.: Company Overview
    • 14.8.2 Biogen Inc.: Product Portfolio
    • 14.8.3 Biogen Inc.: Recent Developments
  • 14.9 Acorda Therapeutics, Inc.
    • 14.9.1 Acorda Therapeutics, Inc.: Company Overview
    • 14.9.2 Acorda Therapeutics, Inc.: Product Portfolio
    • 14.9.3 Acorda Therapeutics, Inc.: Recent Developments
  • 14.10 UCB S.A.
    • 14.10.1 UCB S.A.: Company Overview
    • 14.10.2 UCB S.A.: Product Portfolio

15. Conclusions

  • 15.1.1 Current Leading Segments
  • 15.1.2 Leading Regional Markets
  • 15.1.3 Emerging Markets
  • 15.1.4 The Future of the Market?

Table of Tables

  • Table 3.1. Global Parkinson's Disease Drug Industry and Market Forecast ($bn, AGR%, CAGR%) 2018-2028
  • Table 4.1 Global Parkinson's Disease Market, by Drug Type, Forecast ($bn, AGR%, CAGR%) 2018-2028
  • Table 4.2 Global Parkinson's Disease Market Forecast for Levodopa/Carbidopa Drugs, ($bn, AGR%, CAGR%) 2018-2028
  • Table 4.3 Global Parkinson's Disease Market Forecast for Levodopa/Carbidopa Drugs, by Geography, ($bn, AGR%, CAGR%) 2017-2028
  • Table 4.4 Global Parkinson's Disease Market Forecast for Dopamine Receptor Agonists Drugs, ($bn, AGR%, CAGR%) 2018-2028
  • Table 4.5 Global Parkinson's Disease Market Forecast for Dopamine Receptor Agonists Drugs, by Geography ($bn, AGR%, CAGR%) 2018-2028
  • Table 4.6 Global Parkinson's Disease Market Forecast for MAO-Inhibitors Drugs, ($bn, AGR%, CAGR%) 2018-2028
  • Table 4.7 Global Parkinson's Disease Market Forecast for MAO-Inhibitors Drugs, by Geography ($bn, AGR%, CAGR%) 2018-2028
  • Table 4.8 Global Parkinson's Disease Market Forecast for COMT-inhibitors Drugs, ($bn, AGR%, CAGR%) 2018-2028
  • Table 4.9 Global Parkinson's Disease Market Forecast for COMT-inhibitors Drugs, by Geography ($bn, AGR%, CAGR%) 2018-2028
  • Table 4.10 Global Parkinson's Disease Market Forecast for Anticholinergics Drugs, ($bn, AGR%, CAGR%) 2018-2028
  • Table 4.11 Global Parkinson's Disease Market Forecast for Anticholinergics Drugs, by Geography ($bn, AGR%, CAGR%) 2018-2028
  • Table 4.12 Global Parkinson's Disease Market Forecast for Others Drugs, ($bn, AGR%, CAGR%) 2018-2028
  • Table 4.13 Global Parkinson's Disease Market Forecast for Others Drugs, ($bn, AGR%, CAGR%) 2018-2028
  • Table 5.1. Global Parkinson's Disease Market Forecast for Distribution Channel ($bn, AGR%, CAGR%) 2018-2028
  • Table 5.2 Global Parkinson's Disease Market Forecast for Hospital Pharmacies, ($bn, AGR%, CAGR%) 2018-2028
  • Table 5.3 Global Parkinson's Disease Market Forecast for Hospital Pharmacies, by Geography ($bn, AGR%, CAGR%) 2018-2028
  • Table 5.4 Global Parkinson's Disease Market Forecast for Retailer Pharmacies ($bn, AGR%, CAGR%) 2018-2028
  • Table 5.5 Global Parkinson's Disease Market Forecast for Retailer Pharmacies, by Geography ($bn, AGR%, CAGR%) 2018-2028
  • Table 5.6 Global Parkinson's Disease Market Forecast for Online Pharmacies ($bn, AGR%, CAGR%) 2018-2028
  • Table 5.7 Global Parkinson's Disease Market Forecast for Online Pharmacies, by Geography ($bn, AGR%, CAGR%) 2018-2028
  • Table 6.1 Global Parkinson's Disease Market Forecast for End User ($bn, AGR%, CAGR%) 2018-2028
  • Table 6.2 Global Parkinson's Disease Market Forecast by Hospitals, ($bn, AGR%, CAGR%) 2018-2028
  • Table 6.3 Global Parkinson's Disease Market Forecast by Hospitals, by Geography ($bn, AGR%, CAGR%) 2018-2028
  • Table 6.4 Global Parkinson's Disease Market Forecast by Clinics ($bn, AGR%, CAGR%) 2018-2028
  • Table 6.5 Global Parkinson's Disease Market Forecast by Clinics, by Geography ($bn, AGR%, CAGR%) 2018-2028
  • Table 7.1. Global Parkinson's Disease Market Forecast, by Geography ($bn, AGR%, CAGR%) 2018-2028
  • Table 8.1 North America Parkinson's Disease Drug industry and Forecast, by Country ($bn, AGR%, CAGR%) 2018-2028
  • Table 8.2 US Parkinson's Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
  • Table 8.3 Canada Parkinson's Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
  • Table 8.4 Mexico Parkinson's Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
  • Table 9.1 South America Parkinson's Disease Drug industry and Forecast, by Country ($bn, AGR%, CAGR%) 2018-2028
  • Table 9.2 Brazil Parkinson's Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
  • Table 9.3 Argentina Parkinson's Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
  • Table 9.4 Paraguay Parkinson's Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
  • Table 9.5 Bolivia Parkinson's Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
  • Table 9.6 Rest of South America Parkinson's Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
  • Table 10.1 European Parkinson's Disease Drug industry and Forecast, by Country ($bn, AGR%, CAGR%) 2018-2028
  • Table 10.2 France Parkinson's Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
  • Table 10.3 Germany Parkinson's Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
  • Table 10.4 UK Parkinson's Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
  • Table 10.5 Spain Parkinson's Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
  • Table 10.6 Italy Parkinson's Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
  • Table 10.7 Russia Parkinson's Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
  • Table 10.8 Rest of European Parkinson's Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
  • Table 11.1 Asia-Pacific Parkinson's Disease Drug industry and Forecast, by Country ($bn, AGR%, CAGR%) 2018-2028
  • Table 11.2 China Parkinson's Disease Drug Industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
  • Table 11.3 Japan Parkinson's Disease Drug Industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
  • Table 11.4 India Parkinson's Disease Drug Industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
  • Table 11.5 Australia Parkinson's Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
  • Table 11.6 Thailand Parkinson's Disease Drug Industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
  • Table 11.7 Rest of Asia-Pacific Parkinson's Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
  • Table 12.1 Rest of World Parkinson's Disease Drug industry and Forecast, by Country ($bn, AGR%, CAGR%) 2018-2028
  • Table 12.2 Middle East Parkinson's Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
  • Table 12.3 Africa Parkinson's Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
  • Table 12.4 Other Countries Parkinson's Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
  • Table 14.1 AstraZeneca Plc: Company Overview
  • Table 14.2 AstraZeneca Plc: Product Portfolio
  • Table 14.3 AstraZeneca Plc: Recent Developments
  • Table 14.4 Merck & Co. Inc.: Company Overview
  • Table 14.5 Merck & Co. Inc.: Product Portfolio
  • Table 14.6 Novartis AG: Company Overview
  • Table 14.7 Novartis AG: Product Portfolio
  • Table 14.8 GlaxoSmithKline PLC: Company Overview
  • Table 14.9 GlaxoSmithKline PLC: Product Portfolio
  • Table 14.10 F. Hoffmann-La Roche : Company Overview
  • Table 14.11 F. Hoffmann-La Roche: Product Portfolio
  • Table 14.12 F. Hoffmann-La Roche : Recent Developments
  • Table 14.13 Pfizer Inc.: Company Overview
  • Table 14.14 Pfizer Inc.: Product Portfolio
  • Table 14.15 Pfizer: Recent Developments
  • Table 14.16 Abbvie Inc.: Company Overview
  • Table 14.17 Abbvie Inc.: Product Portfolio
  • Table 14.18 Abbvie Inc.: Recent Developments
  • Table 14.19 Biogen Inc.: Company Overview
  • Table 14.20 Biogen Inc.: Product Portfolio
  • Table 14.21 Biogen Inc.: Recent Developments
  • Table 14.22 Acorda Therapeutics, Inc.: Company Overview
  • Table 14.23 Acorda Therapeutics, Inc.: Product Portfolio
  • Table 14.24 Acorda Therapeutics, Inc.: Recent Developments
  • Table 14.25 UCB S.A.: Company Overview
  • Table 14.26 UCB S.A.: Product Portfolio

Table of Figures

  • Figure 1.1 Global Parkinson's Disease World Drug Market Segmentation
  • Figure 3.1 Parkinson's disease, by Drug Type, ($bn), 2018-2028
  • Figure 3.2 Global Parkinson's Disease Market, by Distribution Channel, ($bn), 2018-2028
  • Figure 3.3 Global Parkinson's Disease Market, by End User, ($bn), 2018-2028
  • Figure 4.1. Global Parkinson's Disease Market Forecast, by Drug Type($bn) 2018-2028
  • Figure 4.2 Global Parkinson's Disease Market, by Drug Type, Market Share (%), 2017
  • Figure 4.3 Global Parkinson's Disease Market Forecast for Levodopa/Carbidopa Drugs, by Geography, ($bn) 2018-2028
  • Figure 4.4 Global Parkinson's Disease Market Forecast for Dopamine Receptor Agonists Drugs, by Geography, ($bn) 2018-2028
  • Figure 4.5 Global Parkinson's Disease Market Forecast for MAO-Inhibitors Drugs, by Geography, ($bn) 2018-2028
  • Figure 4.6 Global Parkinson's Disease Market Forecast for COMT-inhibitors Drugs, by Geography, ($bn) 2018-2028
  • Figure 4.7 Global Parkinson's Disease Market Forecast for Anticholinergics Drugs, by Geography, ($bn) 2018-2028
  • Figure 4.8 Global Parkinson's Disease Market Forecast for Others Drugs, by Geography, ($bn) 2018-2028
  • Figure 5.1. Global Parkinson's Disease Market Forecast for Distribution Channel, Market Share (%), 2017
  • Figure 5.2. Global Parkinson's Disease Market Forecast for Hospital Pharmacies, by Geography ($bn) 2018-2028
  • Figure 5.3 Global Parkinson's Disease Market Forecast for Retailer Pharmacies, by Geography ($bn) 2018-2028
  • Figure 5.4 Global Parkinson's Disease Market Forecast for Online Pharmacies, by Geography ($bn) 2018-2028
  • Figure 6.1 Global Parkinson's Disease Market Forecast for End User, Market Share (%), 2017
  • Figure 6.2 Global Parkinson's Disease Market Forecast by Hospitals, by Geography ($bn) 2018-2028
  • Figure 6.3 Global Parkinson's Disease Market Forecast by Clinics, by Geography ($bn) 2018-2028
  • Figure 7.1. Global Parkinson's Disease Market Forecast, by Geography, by Geography ($bn) 2018-2028
  • Figure 7.2. Global Parkinson's Disease Market Forecast, by Geography, Market Share (%), 2017
  • Figure 8.1 North America Parkinson's Disease Drug industry and Forecast, by Country ($bn) 2018-2028
  • Figure 8.2 North America Parkinson's Disease Drug industry and Forecast, by Country, Market Share (%), 2017
  • Figure 8.3 US Parkinson's Disease Drug industry and Forecast, ($bn) 2018-2028
  • Figure 8.4 Canada Parkinson's Disease Drug industry and Forecast ($bn) 2018-2028
  • Figure 8.5 Mexico Parkinson's Disease Drug industry and Forecast ($bn) 2018-2028
  • Figure 9.1 South America Parkinson's Disease Drug industry and Forecast, by Country ($bn) 2018-2028
  • Figure 9.2 South America Parkinson's Disease Drug industry and Forecast, by Country, Market Share (%), 2017
  • Figure 9.3 Brazil Parkinson's Disease Drug industry and Forecast ($bn) 2018-2028
  • Figure 9.4 Argentina Parkinson's Disease Drug industry and Forecast ($bn) 2018-2028
  • Figure 9.5 Paraguay Parkinson's Disease Drug industry and Forecast ($bn) 2018-2028
  • Figure 9.6 Bolivia Parkinson's Disease Drug industry and Forecast ($bn) 2018-2028
  • Figure 9.7 Rest of South America Parkinson's Disease Drug industry and Forecast ($bn) 2018-2028
  • Figure 10.1 Europe Parkinson's Disease Drug industry and Forecast, by Country ($bn) 2018-2028
  • Figure 10.2 Europe Parkinson's Disease Drug industry and Forecast, by Country, Market Share (%), 2017
  • Figure 10.3 France Parkinson's Disease Drug industry and Forecast ($bn) 2018-2028
  • Figure 10.4 Germany Parkinson's Disease Drug industry and Forecast ($bn) 2018-2028
  • Figure 10.5 UK Parkinson's Disease Drug industry and Forecast ($bn) 2018-2028
  • Figure 10.6 Spain Parkinson's Disease Drug industry and Forecast ($bn) 2018-2028
  • Figure 10.7 Italy Parkinson's Disease Drug industry and Forecast ($bn) 2018-2028
  • Figure 10.8 Russia Parkinson's Disease Drug industry and Forecast ($bn) 2018-2028
  • Figure 10.9 Rest of Europe Parkinson's Disease Drug industry and Forecast ($bn) 2018-2028
  • Figure 11.1 Asia-Pacific Parkinson's Disease Drug industry and Forecast, by Country ($bn) 2018-2028
  • Figure 11.2 Asia-Pacific Parkinson's Disease Drug Industry and Forecast, Market Share (%), 2017
  • Figure 11.3 China Parkinson's Disease Drug Industry and Forecast ($bn) 2018-2028
  • Figure 11.4 Japan Parkinson's Disease Drug Industry and Forecast ($bn) 2018-2028
  • Figure 11.5 India Parkinson's Disease Drug Industry and Forecast ($bn) 2018-2028
  • Figure 11.6 Australia Parkinson's Disease Drug industry and Forecast ($bn) 2018-2028
  • Figure 11.7 Thailand Parkinson's Disease Drug industry and Forecast ($bn) 2018-2028
  • Figure 11.8 Rest of Asia-Pacific Parkinson's Disease Drug industry and Forecast ($bn) 2018-2028
  • Figure 12.1 RoW Parkinson's Disease Drug industry and Forecast, by Country($bn) 2018-2028
  • Figure 12.2 Rest of World Parkinson's Disease Drug industry and Forecast, by Country, Market Share (%), 2017
  • Figure 12.3 Middle East Parkinson's Disease Drug industry and Forecast ($bn) 2018-2028
  • Figure 12.4 Africa Parkinson's Disease Drug Industry and Forecast ($bn) 2018-2028
  • Figure 12.5 Other Countries Parkinson's Disease Drug industry and Forecast ($bn) 2018-2028
  • Figure 13.1 Porter's Five Forces Analysis of the Parkinson's Disease Drug Market
  • Figure 14.1 AstraZeneca Plc, Revenue, ($million), 2012-2016
  • Figure 14.2 AstraZeneca Plc, Product Segments Share (%), 2016
  • Figure 14.3 Merck & Co. Inc., Revenue, ($million), 2012-2016
  • Figure 14.4 Merck & Co. Inc., Product Segments Share (%), 2016
  • Figure 14.5 Merck & Co. Inc., Geographical Presence Share (%), 2016
  • Figure 14.6 Novartis AG, Revenue, ($million), 2012-2016
  • Figure 14.7 Novartis AG, Product Segments Share (%), 2016
  • Figure 14.8 Novartis AG, Geographical Presence Share (%), 2016
  • Figure 14.9 GlaxoSmithKline PLC, Revenue, ($million), 2012-2016
  • Figure 14.10 GlaxoSmithKline PLC, Product Segments Share (%), 2016
  • Figure 14.11 GlaxoSmithKline PLC, Geographical Presence Share (%), 2016
  • Figure 14.12 F. Hoffmann-La Roche, Revenue, ($million), 2012-2016
  • Figure 14.13 F. Hoffmann-La Roche, Product Segments Share (%), 2016
  • Figure 14.14 F. Hoffmann-La Roche, Geographical Presence Share (%), 2016
  • Figure 14.15 Pfizer Inc., Revenue, ($million), 2012-2016
  • Figure 14.16 Pfizer Inc., Product Segments Share (%), 2016
  • Figure 14.17 Pfizer Inc., Geographical Presence Share (%), 2016
  • Figure 14.18 Abbvie Inc., Revenue, ($million), 2012-2016
  • Figure 14.19 Abbvie Inc., Product Segments Share (%), 2016
  • Figure 14.20 Abbvie Inc., Geographical Presence Share (%), 2016
  • Figure 14.21 Biogen Inc., Revenue, ($million), 2012-2016
  • Figure 14.22 Biogen Inc., Product Segments Share (%), 2016
  • Figure 14.23 Biogen Inc., Geographical Presence Share (%), 2016
  • Figure 14.24 Acorda Therapeutics, Inc., Revenue, ($million), 2012-2016
  • Figure 14.25 UCB S.A., Revenue, ($million), 2012-2016
  • Figure 15.1 World Parkinson's Disease Drugs Market, by Drug Class, ($bn), 2018-2028
  • Figure 15.2 World Parkinson's Disease Drugs Market, by Distribution Channel, ($bn), 2018-2028
  • Figure 15.3 World Parkinson's Disease Drugs Market, by End-User, ($bn), 2018-2028
  • Figure 15.4. World Parkinson's Disease Drugs Market, by Geography, ($bn), 2018-2028

Companies Listed

  • Abbvie
  • Acorda Therapeutics Inc.
  • AstraZeneca
  • BioArtic
  • Biogen Inc.
  • Biotie Therapies
  • Center for Disease Control and Prevention (CDC)
  • Civitas Therapeutics
  • Food and Drugs Administration (FDA)
  • GlaxoSmithKline
  • Health Canada
  • IBM
  • Merck & Co.
  • Novartis
  • Parkinson's Association
  • Parkinson's Institute and Clinical Centre
  • Pfizer
  • Pharmaceuticals and Medical Devices Agency (PMDA)
  • Prothena
  • Roche
  • Servizio Sanitario Nazionale (SSN)
  • Takeda
  • UCB S.A
  • World Health Organisation (WHO)
Back to Top